Jessica Söderfjord, who received her Alzheimer's diagnosis at the young age of 54, describes the life-altering moment as if someone had pulled the rug out from under her. This diagnosis has set her on a path of advocacy, stressing the need for Swedish patients in the early stages of the disease to gain access to newly approved Alzheimer medications by the European Medicines Agency (EMA). She feels marginalized, indicating that early-stage patients are often overlooked when it comes to prioritizing treatment options.

Last year marked a significant breakthrough as the EMA approved medications aimed at reducing harmful amyloid plaque buildup in the brains of Alzheimer’s patients, which is crucial since these plaques obstruct neural pathways. However, Jessica points out that the future availability of these treatments in Sweden remains uncertain. Her personal experiences underscore a broader systemic issue within the healthcare framework where the needs of early-stage Alzheimer patients can easily be disregarded, rendering their situation increasingly desperate.

At 56, Jessica shares her struggles with multiple bouts of burnout and an ADHD diagnosis received at 52, emphasizing how these mental health challenges compound her battle with Alzheimer’s. The discussion around available treatments is not just a matter of individual health but raises significant questions about the prioritization of patient care within the Swedish healthcare system, pointing to a critical need for policies that ensure equitable access to life-altering medications for those diagnosed early with impactful diseases like Alzheimer’s.